
    
      (OSKIRA-Asia-1): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group
      Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients with
      Active Rheumatoid Arthritis who are Inadequate Responders to Methotrexate Therapy
    
  